10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by KBC Group NV

KBC Group NV raised its position in 10x Genomics, Inc. (NASDAQ:TXG) by 57.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,072 shares of the company’s stock after buying an additional 1,847 shares during the period. KBC Group NV’s holdings in 10x Genomics were worth $73,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Blue Trust Inc. increased its position in shares of 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after buying an additional 1,299 shares in the last quarter. Sound Income Strategies LLC grew its stake in 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after acquiring an additional 1,330 shares during the period. SG Americas Securities LLC increased its holdings in 10x Genomics by 209.8% in the 4th quarter. SG Americas Securities LLC now owns 73,046 shares of the company’s stock worth $1,049,000 after acquiring an additional 49,468 shares in the last quarter. Nisa Investment Advisors LLC acquired a new position in 10x Genomics during the fourth quarter worth $237,000. Finally, MCF Advisors LLC purchased a new position in 10x Genomics during the fourth quarter valued at $92,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Price Performance

NASDAQ:TXG opened at $12.06 on Tuesday. The company’s 50-day moving average is $14.98 and its two-hundred day moving average is $17.56. 10x Genomics, Inc. has a 1-year low of $11.90 and a 1-year high of $51.22. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -7.88 and a beta of 1.85.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TXG. Morgan Stanley cut their target price on shares of 10x Genomics from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, February 1st. JPMorgan Chase & Co. decreased their target price on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. UBS Group lowered their price target on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. Finally, Barclays reduced their price objective on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Monday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $23.79.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.